Molbio Diagnostics IPO Day 1 Subscription Status: 0.83x Subscribed; GMP at ₹138
Molbio Diagnostics’ IPO reached 0.83 times subscription on Day 1, as of early evening on 10 August 2026. The employee portion led at 2.12 times, while Qualified Institutional Buyers (QIBs) reached 1.00 times. The latest available Grey Market Premium (GMP) was ₹138 on 10 August. The issue remains open and closes on 12 August 2026.
| Metric | Latest update |
| Bidding day | Day 1 |
| Data status | Early evening (5:00 p.m. to 6:29 p.m. IST) on 10 August 2026 |
| Overall subscription | 0.83x |
| QIB subscription | 1.00x |
| Non-Institutional Investors (NIIs) | 0.73x |
| Retail subscription | 0.77x |
| Employee subscription | 2.12x |
| Current GMP | ₹138 |
| GMP percentage | 17.1% |
| Indicative price | ₹945 |
| Closing date | 12 August 2026 |
Molbio Diagnostics IPO Day 1 Subscription Status
Molbio Diagnostics received bids for about 67.67 lakh shares against 81.58 lakh shares available for public bidding, taking the overall Day 1 subscription to 0.83 times. The figures remain Day 1 data rather than final IPO subscription numbers because bidding continues for another two days.
| Investor category | Day 1 subscription |
| Qualified Institutional Buyers (QIBs) | 1.00x |
| Non-Institutional Investors (NIIs) | 0.73x |
| Retail Individual Investors | 0.77x |
| Eligible employees | 2.12x |
| Overall | 0.83x |
The employee reservation was the most subscribed category, while QIB demand reached the shares available to that segment. Retail and NII demand remained below one time at the end of the available Day 1 update.
Subscription multiples measure the quantity of shares bid for relative to the shares reserved for each category. They do not represent the number of unique applicants, and a smaller reserved category can reach a higher multiple more quickly.
What the Day 1 Subscription Numbers Indicate So Far
The opening-day response was reasonably spread across categories, although it was not yet fully subscribed overall. Employee demand was strongest, QIBs reached 1.00 times, and retail and NII bids were at 0.77 times and 0.73 times, respectively.
Institutional participation in book-built IPOs can build later in the bidding period, but Day 1 numbers alone do not establish how QIB demand will develop. The more useful Day 2 signal will be whether overall demand moves above one time and whether retail, NII, and institutional participation strengthens together.
Molbio Diagnostics IPO GMP Today and Estimated Listing Price
The latest available Molbio Diagnostics IPO GMP was ₹138 on 10 August 2026, compared with ₹132 on 9 August. This represents an increase of ₹6 from the previous available reading. One tracker had earlier reported ₹132 on Day 1, while other same-day market reports cited readings around ₹120, highlighting that GMP observations can differ across the unofficial market.
| GMP metric | Value |
| Current GMP | ₹138 |
| Previous available GMP | ₹132 |
| Movement | Up ₹6 |
| Upper price band | ₹807 |
| GMP percentage | 17.1% |
| Indicative price | ₹945 |
At a ₹138 GMP, the indicative price works out to ₹807 + ₹138 = ₹945. The GMP percentage is about 17.1% of the upper price band.
GMP is an unofficial, unregulated market indicator. It can change quickly, different trackers may report different values, and it does not guarantee either the actual listing price or a listing gain.
What Stands Out in Today’s Bidding
Two points are notable. First, Day 1 demand was not confined to one main investor category, with QIB, NII, and retail participation all reaching meaningful levels. Second, the employee reservation crossed two times subscription while the total issue remained at 0.83 times.
There are also important limitations. Day 1 is only the opening stage of a three-day bidding window, so current multiples can change substantially. Further, a positive GMP and rising subscription do not prove that the IPO is fairly valued, that the underlying business is high quality, or that the shares will deliver positive listing or long-term returns.
IPO Details Retail Investors Need
| IPO detail | Information |
| Price band | ₹768 to ₹807 per share |
| Lot size | 18 shares |
| Minimum retail investment | ₹14,526 |
| Total issue size | ₹939.70 crore |
| Fresh issue | ₹200 crore |
| Offer for Sale (OFS) | ₹739.70 crore |
| Issue type | Book-built mainboard IPO |
| Closing date | 12 August 2026 |
| Expected listing date | 17 August 2026 |
| Exchange | BSE and NSE |
The offer consists of a ₹200 crore fresh issue and an Offer for Sale (OFS) of about ₹739.70 crore. The minimum retail application of 18 shares costs ₹14,526 at the upper price band.
Brief Company and Financial Context
Molbio Diagnostics develops point-of-care molecular diagnostic products, led by its portable Truenat platform. In fiscal 2026, revenue from operations rose 41.7% to about ₹1,445.69 crore from ₹1,020.42 crore, while restated profit increased to ₹164.14 crore from ₹138.58 crore. Test kits are a major revenue driver.
Fresh-issue proceeds are intended mainly for research and development infrastructure, a Centre of Excellence, manufacturing equipment, and general corporate purposes. A material risk is customer concentration. The largest customer represented 56.52% of finished-goods product revenue in fiscal 2026, while the top 10 accounted for 83.26%.
What Happens Next
Day 2 bidding will show whether the IPO moves beyond full subscription and whether demand becomes broader across retail, NII, and QIB categories. Investors can also monitor whether the GMP holds near current levels, rises, or weakens. The IPO remains open through 12 August 2026, so Day 1 should be treated as an opening snapshot rather than a final demand verdict.
Frequently Asked Questions (FAQs)
Q: How many times was the Molbio Diagnostics IPO subscribed on Day 1?
A: The Molbio Diagnostics IPO was subscribed 0.83 times on Day 1, based on the latest available exchange-reported bidding data for 10 August 2026. QIBs reached 1.00 times, NIIs 0.73 times, retail 0.77 times, and employees 2.12 times.
Q: What is the Molbio Diagnostics IPO GMP today?
A: The latest available GMP was ₹138 on 10 August 2026, up from ₹132 on the previous available reading. GMP is unofficial, and other same-day readings have differed, so it should not be treated as an exchange-verified price.
Q: What listing price does the current Molbio Diagnostics IPO GMP indicate?
A: A ₹138 GMP over the ₹807 upper price band gives an indicative price of ₹945 per share, equivalent to a premium of about 17.1%. This is only a grey-market indication and is not a forecast or guarantee of the actual listing price.
Q: Does high IPO subscription guarantee a premium listing?
A: No. Subscription measures bidding demand relative to shares available, while listing performance can depend on valuation, market conditions, company fundamentals, and investor sentiment. Even a heavily subscribed IPO can list below expectations, and GMP can change sharply before listing.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
